{
  "hash": "3fbff71fc145382b55223c5e39695e6e",
  "result": {
    "engine": "jupyter",
    "markdown": "---\ntitle: \"Clinical Trial Watch\"\n---\n\n## Monitoring Status\n\nThis page monitors specific clinical trials and highlights any updates in their status or key fields.\n\n[Download Status Summary (CSV)](data/status_summary.csv)\n\n| Trial ID | Sponsor | Update | Status | Conditions | Phases | Start | End | Enroll | Last Updated |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| [NCT04818619](https://clinicaltrials.gov/study/NCT04818619) | Assiut University |  No Change | UNKNOWN | Chronic Myeloid Leukemia | N/A | 2021-04 | 2022-12 | 65 | 2021-03-25 |\n| [NCT04150965](https://clinicaltrials.gov/study/NCT04150965) | Multiple Myeloma Research Consortium |  No Change | TERMINATED | Multiple Myeloma, Relapsed Refractory Multiple Myeloma | PHASE1, PHASE2 | 2020-07-10 | 2024-08-30 | 14 | 2025-02-12 |\n| [NCT05607563](https://clinicaltrials.gov/study/NCT05607563) | Biotheus Inc. |  No Change | UNKNOWN | Advanced Tumor | PHASE1 | 2022-11-21 | 2023-12 | 54 | 2023-02-07 |\n| [NCT05394168](https://clinicaltrials.gov/study/NCT05394168) | Shanghai Henlius Biotech |  No Change | ACTIVE_NOT_RECRUITING | Advanced/Metastatic Solid Tumors | PHASE1 | 2022-12-09 | 2025-03-04 | 12 | 2024-03-28 |\n| [NCT07171307](https://clinicaltrials.gov/study/NCT07171307) | Instituto de Oftalmolog铆a Fundaci贸n Conde de Valenciana |  No Change | NOT_YET_RECRUITING | Conjunctivitis, Allergic | N/A | 2026-01-01 | 2026-09 | 60 | 2025-09-15 |\n| [NCT04995523](https://clinicaltrials.gov/study/NCT04995523) | AstraZeneca |  No Change | RECRUITING | Non-Small-Cell Lung Carcinoma | PHASE1, PHASE2 | 2021-09-14 | 2028-03-16 | 210 | 2025-11-21 |\n| [NCT03119428](https://clinicaltrials.gov/study/NCT03119428) | OncoMed Pharmaceuticals, Inc. |  No Change | TERMINATED | Locally Advanced Cancer, Metastatic Cancer | PHASE1 | 2017-05-02 | 2019-05-15 | 33 | 2020-08-10 |\n| [NCT04500678](https://clinicaltrials.gov/study/NCT04500678) | University of Hawaii |  No Change | UNKNOWN | HIV/AIDS | PHASE2, PHASE3 | 2019-02-01 | 2022-12-31 | 38 | 2020-08-04 |\n| [NCT05483400](https://clinicaltrials.gov/study/NCT05483400) | University Medical Center Groningen |  No Change | RECRUITING | Head and Neck Neoplasms, MSI-H Cancer, Melanoma | PHASE2 | 2023-10-18 | 2027-09 | 97 | 2025-03-28 |\n| [NCT05390528](https://clinicaltrials.gov/study/NCT05390528) | Shanghai Henlius Biotech |  No Change | UNKNOWN | Advanced Tumors, Lymphoma, Metastatic Tumors | PHASE1, PHASE2 | 2022-06-20 | 2024-12-30 | 30 | 2023-08-07 |\n| [NCT06250036](https://clinicaltrials.gov/study/NCT06250036) | Royal Marsden NHS Foundation Trust |  No Change | RECRUITING | Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer | PHASE2 | 2025-02-20 | 2031-09-01 | 50 | 2025-08-19 |\n| [NCT05653284](https://clinicaltrials.gov/study/NCT05653284) | Akeso |  No Change | COMPLETED | Advanced Malignant Tumors | PHASE1 | 2023-02-09 | 2024-05-30 | 19 | 2024-08-11 |\n| [NCT05102214](https://clinicaltrials.gov/study/NCT05102214) | Shanghai Henlius Biotech |  No Change | UNKNOWN | Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer | PHASE1, PHASE2 | 2022-05-03 | 2024-02 | 150 | 2023-08-07 |\n| [NCT05023109](https://clinicaltrials.gov/study/NCT05023109) | Shanghai Zhongshan Hospital |  No Change | UNKNOWN | Biliary Tract Carcinoma | PHASE2 | 2021-02-01 | 2024-12-01 | 45 | 2023-08-12 |\n| [NCT05130177](https://clinicaltrials.gov/study/NCT05130177) | Diwakar Davar |  No Change | RECRUITING | Melanoma | PHASE2 | 2022-03-16 | 2031-01 | 26 | 2025-05-02 |\n| [NCT04047862](https://clinicaltrials.gov/study/NCT04047862) | BeiGene |  No Change | COMPLETED | Locally Advanced and Metastatic Solid Tumors | PHASE1 | 2019-08-15 | 2024-08-07 | 446 | 2025-08-04 |\n| [NCT05537051](https://clinicaltrials.gov/study/NCT05537051) | Biotheus Inc. |  No Change | UNKNOWN | Advanced Solid Tumours | PHASE1 | 2023-10-30 | 2025-12-31 | 30 | 2023-02-07 |\n| [NCT05019677](https://clinicaltrials.gov/study/NCT05019677) | Fudan University |  No Change | WITHDRAWN | Intrahepatic Cholangiocarcinoma | PHASE2 | 2021-09-01 | 2024-12-01 | 0 | 2022-03-22 |\n| [NCT05061628](https://clinicaltrials.gov/study/NCT05061628) | Shanghai Junshi Bioscience Co., Ltd. |  No Change | UNKNOWN | Advanced Tumors | PHASE1 | 2021-04-21 | 2024-09-30 | 176 | 2021-09-21 |\n| [NCT04656535](https://clinicaltrials.gov/study/NCT04656535) | Yale University |  No Change | ACTIVE_NOT_RECRUITING | Glioblastoma | EARLY_PHASE1 | 2021-04-21 | 2026-12-31 | 46 | 2026-01-06 |\n| [NCT06773507](https://clinicaltrials.gov/study/NCT06773507) | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. |  No Change | RECRUITING | Advanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC) | PHASE1 | 2025-05-12 | 2027-06 | 80 | 2025-07-07 |\n| [NCT06349980](https://clinicaltrials.gov/study/NCT06349980) | Shanghai Henlius Biotech |  No Change | RECRUITING | Carcinoma, Hepatocellular | PHASE2 | 2024-08-05 | 2027-02-10 | 117 | 2024-12-15 |\n| [NCT05706207](https://clinicaltrials.gov/study/NCT05706207) | Huabo Biopharm Co., Ltd. |  No Change | UNKNOWN | Advanced Solid Tumor | PHASE1 | 2021-12-21 | 2023-09-30 | 36 | 2023-01-20 |\n| [NCT05060432](https://clinicaltrials.gov/study/NCT05060432) | iTeos Belgium SA |  No Change | ACTIVE_NOT_RECRUITING | Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma | PHASE1, PHASE2 | 2021-09-06 | 2025-07 | 153 | 2024-06-19 |\n| [NCT06713798](https://clinicaltrials.gov/study/NCT06713798) | Gustave Roussy, Cancer Campus, Grand Paris |  No Change | NOT_YET_RECRUITING | Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer | PHASE2 | 2025-07 | 2030-01 | 115 | 2025-06-23 |\n| [NCT05394337](https://clinicaltrials.gov/study/NCT05394337) | M.D. Anderson Cancer Center |  No Change | RECRUITING | Metastatic Malignancy | PHASE1, PHASE2 | 2023-02-23 | 2025-12-31 | 10 | 2025-10-07 |\n| [NCT05253105](https://clinicaltrials.gov/study/NCT05253105) | Shanghai Junshi Bioscience Co., Ltd. |  No Change | WITHDRAWN | Previously Treated, Advanced, Malignancies | PHASE1 | 2022-03-15 | 2027-01 | 0 | 2022-05-24 |\n| [NCT04270942](https://clinicaltrials.gov/study/NCT04270942) | Provention Bio, a Sanofi Company |  No Change | COMPLETED | Diabetes Mellitus, Type 1 | PHASE2 | 2020-02-26 | 2024-01-22 | 6 | 2025-01-20 |\n| [NCT05294952](https://clinicaltrials.gov/study/NCT05294952) | Assiut University |  No Change | NOT_YET_RECRUITING | Pre-Eclampsia | PHASE4 | 2025-01-01 | 2025-11-04 | 82 | 2024-02-01 |\n| [NCT06754501](https://clinicaltrials.gov/study/NCT06754501) | M.D. Anderson Cancer Center |  No Change | RECRUITING | Cancer | PHASE2 | 2025-04-11 | 2029-07-01 | 35 | 2025-10-01 |\n| [NCT05757492](https://clinicaltrials.gov/study/NCT05757492) | Coherus Oncology, Inc. |  No Change | TERMINATED | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | PHASE1 | 2023-04-26 | 2024-07-31 | 22 | 2025-04-30 |\n| [NCT04952597](https://clinicaltrials.gov/study/NCT04952597) | BeiGene |  No Change | COMPLETED | Limited Stage Small Cell Lung Cancer | PHASE2 | 2021-07-15 | 2023-07-26 | 126 | 2024-10-23 |\n| [NCT05805501](https://clinicaltrials.gov/study/NCT05805501) | Hoffmann-La Roche |  No Change | ACTIVE_NOT_RECRUITING | Renal Cell Carcinoma | PHASE2 | 2023-04-21 | 2026-07-31 | 199 | 2025-11-12 |\n| [NCT03447678](https://clinicaltrials.gov/study/NCT03447678) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |  No Change | UNKNOWN | Non Small Cell Lung Cancer (NSCLC) | PHASE2 | 2018-05-23 | 2022-05-31 | 65 | 2021-06-08 |\n| [NCT04672369](https://clinicaltrials.gov/study/NCT04672369) | Innovent Biologics (Suzhou) Co. Ltd. |  No Change | COMPLETED | Advanced Lung Cancer | PHASE1 | 2021-06-06 | 2023-06-01 | 42 | 2023-06-18 |\n| [NCT04672356](https://clinicaltrials.gov/study/NCT04672356) | Innovent Biologics (Suzhou) Co. Ltd. |  No Change | COMPLETED | Advanced Lung Cancer | PHASE1 | 2021-01-25 | 2023-06-01 | 19 | 2023-06-18 |\n| [NCT05009069](https://clinicaltrials.gov/study/NCT05009069) | Hoffmann-La Roche |  No Change | ACTIVE_NOT_RECRUITING | Rectal Neoplasms, Rectal Cancer | PHASE2 | 2022-03-18 | 2026-11-06 | 58 | 2026-01-16 |\n| [NCT04353830](https://clinicaltrials.gov/study/NCT04353830) | Innovent Biologics (Suzhou) Co. Ltd. |  No Change | COMPLETED | Advanced Malignancies | PHASE1 | 2020-05-22 | 2022-05-11 | 34 | 2023-02-28 |\n| [NCT07337447](https://clinicaltrials.gov/study/NCT07337447) | Hospices Civils de Lyon |  No Change | NOT_YET_RECRUITING | Carcinoma, Neuroendocrine | PHASE2 | 2026-04 | 2030-04 | 122 | 2026-01-07 |\n| [NCT04354246](https://clinicaltrials.gov/study/NCT04354246) | Compugen Ltd |  No Change | ACTIVE_NOT_RECRUITING | Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC | PHASE1 | 2020-03-31 | 2025-12-30 | 110 | 2025-05-18 |\n| [NCT04933227](https://clinicaltrials.gov/study/NCT04933227) | Hoffmann-La Roche |  No Change | TERMINATED | Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | PHASE2 | 2021-08-06 | 2023-11-17 | 29 | 2024-11-11 |\n| [NCT05414032](https://clinicaltrials.gov/study/NCT05414032) | University Health Network, Toronto |  No Change | RECRUITING | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | PHASE2 | 2023-07-12 | 2026-07 | 200 | 2025-03-25 |\n| [NCT06003621](https://clinicaltrials.gov/study/NCT06003621) | Omico |  No Change | RECRUITING | Solid Tumor, Adult | PHASE2 | 2023-12-15 | 2028-11-01 | 96 | 2024-11-13 |\n| [NCT05568095](https://clinicaltrials.gov/study/NCT05568095) | Arcus Biosciences, Inc. |  No Change | ACTIVE_NOT_RECRUITING | Advanced Upper Gastrointestinal Tract Adenocarcinoma | PHASE3 | 2022-11-21 | 2026-06 | 1040 | 2026-01-30 |\n| [NCT06777628](https://clinicaltrials.gov/study/NCT06777628) | IRCCS Azienda Ospedaliero-Universitaria di Bologna |  No Change | RECRUITING | Liver Cancer, Adult | N/A | 2024-09-15 | 2028-10-15 | 100 | 2025-01-14 |\n| [NCT06773481](https://clinicaltrials.gov/study/NCT06773481) | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. |  No Change | RECRUITING | Glioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHO Grade IV | PHASE1 | 2025-04-07 | 2026-12 | 40 | 2025-07-07 |\n| [NCT03708224](https://clinicaltrials.gov/study/NCT03708224) | Alain Algazi |  No Change | RECRUITING | Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer | PHASE2 | 2019-03-08 | 2028-06-30 | 55 | 2025-01-24 |\n| [NCT03652402](https://clinicaltrials.gov/study/NCT03652402) | Assistance Publique - H么pitaux de Paris |  No Change | COMPLETED | Kidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis | N/A | 2018-11-27 | 2021-10-28 | 558 | 2024-06-04 |\n| [NCT03486119](https://clinicaltrials.gov/study/NCT03486119) | Yonsei University |  No Change | COMPLETED | Non -Small Cell Lung Cancer | N/A | 2018-02-05 | 2020-07-07 | 60 | 2020-10-14 |\n| [NCT05120375](https://clinicaltrials.gov/study/NCT05120375) | Bio-Thera Solutions |  No Change | TERMINATED | Solid Tumor | PHASE1 | 2022-02-17 | 2023-04-07 | 5 | 2023-10-08 |\n| [NCT05327530](https://clinicaltrials.gov/study/NCT05327530) | EMD Serono Research & Development Institute, Inc. |  No Change | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic Urothelial Carcinoma | PHASE2 | 2022-08-17 | 2026-06-25 | 256 | 2026-01-23 |\n| [NCT04570839](https://clinicaltrials.gov/study/NCT04570839) | Compugen Ltd |  No Change | COMPLETED | Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer | PHASE1, PHASE2 | 2020-08-31 | 2024-05-15 | 48 | 2024-07-17 |\n| [NCT05520294](https://clinicaltrials.gov/study/NCT05520294) | University of Colorado, Denver |  No Change | ACTIVE_NOT_RECRUITING | Melanoma | N/A | 2022-09-01 | 2024-08-31 | 90 | 2024-04-15 |\n| [NCT05417321](https://clinicaltrials.gov/study/NCT05417321) | Shanghai Huaota Biopharmaceutical Co., Ltd. |  No Change | RECRUITING | Advanced Solid Tumor, NSCLC | PHASE1, PHASE2 | 2022-08-25 | 2025-08-01 | 80 | 2025-01-02 |\n| [NCT06328036](https://clinicaltrials.gov/study/NCT06328036) | National Cancer Institute (NCI) |  No Change | WITHDRAWN | Recurrent Glioblastoma, IDH-Wildtype | PHASE2 | 2025-04-30 | 2025-07-01 | 0 | 2024-12-27 |\n| [NCT04465643](https://clinicaltrials.gov/study/NCT04465643) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |  No Change | COMPLETED | Nerve Sheath Tumors | PHASE1 | 2021-06-08 | 2025-07-30 | 13 | 2025-10-02 |\n| [NCT04262856](https://clinicaltrials.gov/study/NCT04262856) | Arcus Biosciences, Inc. |  No Change | COMPLETED | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer | PHASE2 | 2020-05-28 | 2025-07-09 | 151 | 2025-08-25 |\n| [NCT04736173](https://clinicaltrials.gov/study/NCT04736173) | Arcus Biosciences, Inc. |  No Change | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer | PHASE2 | 2021-02-08 | 2027-05 | 169 | 2025-12-09 |\n| [NCT05126537](https://clinicaltrials.gov/study/NCT05126537) | Southeast University, China |  No Change | UNKNOWN | 28 Day Mortality | N/A | 2022-01-01 | 2022-12-31 | 100 | 2022-11-25 |\n| [NCT05289492](https://clinicaltrials.gov/study/NCT05289492) | iTeos Therapeutics |  No Change | TERMINATED | Multiple Myeloma | PHASE1 | 2022-05-01 | 2023-11-29 | 16 | 2024-10-23 |\n| [NCT07115043](https://clinicaltrials.gov/study/NCT07115043) | AstraZeneca |  No Change | RECRUITING | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma | PHASE1, PHASE2 | 2025-07-29 | 2029-10-02 | 60 | 2025-12-18 |\n| [NCT05743504](https://clinicaltrials.gov/study/NCT05743504) | National Taiwan University Hospital |  No Change | UNKNOWN | Locally Advanced Esophageal Squamous Cell Carcinoma | PHASE1, PHASE2 | 2023-09-18 | 2025-11-30 | 32 | 2024-01-31 |\n| [NCT05073484](https://clinicaltrials.gov/study/NCT05073484) | Bio-Thera Solutions |  No Change | TERMINATED | Advanced Solid Tumor | PHASE1 | 2021-10-29 | 2023-03-30 | 13 | 2023-10-09 |\n| [NCT07376512](https://clinicaltrials.gov/study/NCT07376512) | Centre Georges Francois Leclerc |  No Change | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer, Melanoma (Skin Cancer) | N/A | 2026-03-01 | 2030-03-01 | 378 | 2026-01-22 |\n| [NCT05904886](https://clinicaltrials.gov/study/NCT05904886) | Hoffmann-La Roche |  No Change | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma | PHASE3 | 2023-09-14 | 2026-09-01 | 687 | 2025-12-30 |\n| [NCT03739710](https://clinicaltrials.gov/study/NCT03739710) | GlaxoSmithKline |  No Change | COMPLETED | Neoplasms | PHASE2 | 2019-01-24 | 2024-05-02 | 175 | 2025-06-13 |\n| [NCT04791839](https://clinicaltrials.gov/study/NCT04791839) | Washington University School of Medicine |  No Change | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer | PHASE2 | 2021-08-04 | 2030-06-30 | 30 | 2025-11-04 |\n| [NCT05020912](https://clinicaltrials.gov/study/NCT05020912) | Case Comprehensive Cancer Center |  No Change | RECRUITING | Basal Cell Carcinoma | PHASE2 | 2021-12-13 | 2027-12 | 28 | 2025-11-25 |\n| [NCT06334406](https://clinicaltrials.gov/study/NCT06334406) | Centre Hospitalier Universitaire de Besancon |  No Change | NOT_YET_RECRUITING | Bladder Cancer | N/A | 2024-04-02 | 2026-04-02 | 33 | 2024-03-19 |\n| [NCT07343310](https://clinicaltrials.gov/study/NCT07343310) | Kine Sciences Co., Ltd. |  No Change | COMPLETED | CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | PHASE1 | 2024-08-27 | 2025-04-14 | 9 | 2026-01-15 |\n| [NCT03342417](https://clinicaltrials.gov/study/NCT03342417) | ExcellaBio LLC |  No Change | TERMINATED | Breast Cancer Female, Ovarian Cancer, Gastric Cancer | PHASE2 | 2018-02-14 | 2019-05-29 | 5 | 2021-11-05 |\n| [NCT04682665](https://clinicaltrials.gov/study/NCT04682665) | University of Leeds |  No Change | COMPLETED | Colon Cancer Liver Metastasis | N/A | 2021-09-16 | 2024-07-31 | 81 | 2024-12-03 |\n| [NCT05123482](https://clinicaltrials.gov/study/NCT05123482) | AstraZeneca |  No Change | RECRUITING | Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer | PHASE1, PHASE2 | 2021-10-18 | 2027-09-29 | 460 | 2025-12-02 |\n| [NCT07161414](https://clinicaltrials.gov/study/NCT07161414) | AstraZeneca |  No Change | RECRUITING | Advanced Solid Tumors | PHASE1 | 2025-11-25 | 2029-07-24 | 40 | 2025-12-18 |\n| [NCT07015164](https://clinicaltrials.gov/study/NCT07015164) | Assistance Publique - H么pitaux de Paris |  No Change | NOT_YET_RECRUITING | HIV | N/A | 2025-06-10 | 2026-09-11 | 80 | 2025-06-03 |\n| [NCT05702229](https://clinicaltrials.gov/study/NCT05702229) | AstraZeneca |  No Change | RECRUITING | Gastric Cancer | PHASE2 | 2023-01-16 | 2027-09-28 | 240 | 2025-11-14 |\n| [NCT07213882](https://clinicaltrials.gov/study/NCT07213882) | Assistance Publique - H么pitaux de Paris |  No Change | NOT_YET_RECRUITING | Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome | EARLY_PHASE1 | 2026-01-01 | 2028-08-01 | 30 | 2025-10-02 |\n| [NCT03628677](https://clinicaltrials.gov/study/NCT03628677) | Arcus Biosciences, Inc. |  No Change | COMPLETED | Solid Tumor, Unspecified, Adult | PHASE1 | 2018-09-12 | 2025-01-23 | 75 | 2025-02-03 |\n| [NCT06897436](https://clinicaltrials.gov/study/NCT06897436) | Medical University of Lublin |  No Change | NOT_YET_RECRUITING | Endometriosis | N/A | 2025-05-01 | 2029-12-31 | 60 | 2025-03-24 |\n| [NCT05633927](https://clinicaltrials.gov/study/NCT05633927) | Hospitales Universitarios Virgen del Roc铆o |  No Change | COMPLETED | SARS-CoV-2 RNA Vaccines, HIV Infection | N/A | 2021-04-01 | 2022-12-01 | 48 | 2024-10-09 |\n| [NCT04836507](https://clinicaltrials.gov/study/NCT04836507) | Curocell Inc. |  No Change | RECRUITING | Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL) | PHASE1, PHASE2 | 2021-03-02 | 2028-02 | 91 | 2021-04-29 |\n| [NCT05775159](https://clinicaltrials.gov/study/NCT05775159) | AstraZeneca |  No Change | RECRUITING | Hepatocellular Carcinoma, Biliary Tract Cancer | PHASE2 | 2023-04-24 | 2027-10-28 | 294 | 2025-11-12 |\n| [NCT06338657](https://clinicaltrials.gov/study/NCT06338657) | University of Southern California |  No Change | TERMINATED | Head and Neck Squamous Cell Carcinoma | PHASE1 | 2024-04-01 | 2025-09-09 | 1 | 2025-09-09 |\n| [NCT06860815](https://clinicaltrials.gov/study/NCT06860815) | City of Hope Medical Center |  No Change | RECRUITING | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver | PHASE2 | 2026-04-01 | 2027-01-30 | 11 | 2026-01-27 |\n| [NCT04624828](https://clinicaltrials.gov/study/NCT04624828) | Istituto Clinico Humanitas |  No Change | ACTIVE_NOT_RECRUITING | Oligorecurrent and Oligoprogressive Prostate Cancer Patients | NA | 2020-10-19 | 2026-07 | 40 | 2025-04-22 |\n| [NCT05574335](https://clinicaltrials.gov/study/NCT05574335) | National Institute of Allergy and Infectious Diseases (NIAID) |  No Change | TERMINATED | Type 1 Diabetes Mellitus | PHASE1, PHASE2 | 2023-04-26 | 2025-10-20 | 8 | 2026-01-05 |\n| [NCT06302556](https://clinicaltrials.gov/study/NCT06302556) | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |  No Change | NOT_YET_RECRUITING | Lung Transplant Rejection | N/A | 2024-04 | 2026-02 | 280 | 2024-03-06 |\n| [NCT04761198](https://clinicaltrials.gov/study/NCT04761198) | Mereo BioPharma |  No Change | COMPLETED | Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor | PHASE1, PHASE2 | 2021-03-23 | 2023-10-30 | 76 | 2025-03-07 |\n| [NCT04693234](https://clinicaltrials.gov/study/NCT04693234) | BeiGene |  No Change | COMPLETED | Cervical Cancer | PHASE2 | 2021-02-15 | 2023-08-31 | 178 | 2025-04-09 |\n| [NCT03563716](https://clinicaltrials.gov/study/NCT03563716) | Genentech, Inc. |  No Change | COMPLETED | Non-small Cell Lung Cancer | PHASE2 | 2018-08-10 | 2025-11-24 | 135 | 2025-12-30 |\n| [NCT07324642](https://clinicaltrials.gov/study/NCT07324642) | Kine Sciences Co., Ltd. |  No Change | COMPLETED | Healthy Volunteers | PHASE1 | 2025-05-26 | 2025-08-25 | 24 | 2025-12-24 |\n| [NCT05809895](https://clinicaltrials.gov/study/NCT05809895) | Novartis Pharmaceuticals |  No Change | WITHDRAWN | Triple Negative Breast Cancer | PHASE2 | 2023-09-15 | 2029-07-18 | 0 | 2023-07-21 |\n| [NCT04732494](https://clinicaltrials.gov/study/NCT04732494) | BeiGene |  No Change | COMPLETED | Esophageal Squamous Cell Carcinoma | PHASE2 | 2021-03-31 | 2023-12-26 | 125 | 2024-12-23 |\n| [NCT05645692](https://clinicaltrials.gov/study/NCT05645692) | Hoffmann-La Roche |  No Change | ACTIVE_NOT_RECRUITING | Urothelial Cancer | PHASE2 | 2023-04-13 | 2026-12-31 | 204 | 2026-01-28 |\n| [NCT04457778](https://clinicaltrials.gov/study/NCT04457778) | EMD Serono Research & Development Institute, Inc. |  No Change | COMPLETED | Metastatic Solid Tumors | PHASE1 | 2020-07-10 | 2023-06-23 | 58 | 2023-12-07 |\n| [NCT03772899](https://clinicaltrials.gov/study/NCT03772899) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |  No Change | ACTIVE_NOT_RECRUITING | Melanoma | PHASE1 | 2019-03-27 | 2026-08 | 20 | 2025-03-26 |\n| [NCT04374877](https://clinicaltrials.gov/study/NCT04374877) | Coherus Oncology, Inc. |  No Change | COMPLETED | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | PHASE1 | 2020-04-22 | 2025-06-05 | 145 | 2025-11-06 |\n| [NCT06346197](https://clinicaltrials.gov/study/NCT06346197) | Centre Leon Berard |  No Change | RECRUITING | Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer | PHASE3 | 2025-12-08 | 2028-05-15 | 132 | 2025-12-19 |\n| [NCT05780073](https://clinicaltrials.gov/study/NCT05780073) | Fundaci贸 Institut Germans Trias i Pujol |  No Change | COMPLETED | HIV Infection Primary | PHASE2 | 2023-10-16 | 2025-04-01 | 60 | 2025-09-16 |\n| [NCT03667716](https://clinicaltrials.gov/study/NCT03667716) | Compugen Ltd |  No Change | COMPLETED | Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer | PHASE1 | 2018-09-06 | 2024-01-30 | 121 | 2025-01-15 |\n| [NCT06784947](https://clinicaltrials.gov/study/NCT06784947) | University of Colorado, Denver |  No Change | ACTIVE_NOT_RECRUITING | Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV | PHASE2 | 2025-03-25 | 2028-05 | 13 | 2025-10-01 |\n| [NCT05014815](https://clinicaltrials.gov/study/NCT05014815) | BeiGene |  No Change | COMPLETED | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV | PHASE2 | 2021-11-16 | 2024-09-04 | 272 | 2025-08-28 |\n| [NCT07307053](https://clinicaltrials.gov/study/NCT07307053) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |  No Change | NOT_YET_RECRUITING | Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors | PHASE1, PHASE2 | 2026-01-01 | 2031-01-31 | 600 | 2025-12-13 |\n| [NCT04746924](https://clinicaltrials.gov/study/NCT04746924) | BeiGene |  No Change | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer, NSCLC | PHASE3 | 2021-06-08 | 2026-03-31 | 662 | 2025-06-23 |\n| [NCT07098338](https://clinicaltrials.gov/study/NCT07098338) | AstraZeneca |  No Change | RECRUITING | Non-Small Cell Lung Cancer | PHASE2 | 2025-08-07 | 2029-04-06 | 278 | 2025-09-25 |\n| [NCT06532539](https://clinicaltrials.gov/study/NCT06532539) | Shandong Cancer Hospital and Institute |  No Change | RECRUITING | Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis | PHASE2 | 2024-06-13 | 2026-05 | 30 | 2024-07-29 |\n| [NCT06864598](https://clinicaltrials.gov/study/NCT06864598) | Peking University People's Hospital |  No Change | ENROLLING_BY_INVITATION | Graft-versus-host Disease (GVHD) | N/A | 2025-01-09 | 2026-10-31 | 100 | 2025-03-04 |\n| [NCT03661047](https://clinicaltrials.gov/study/NCT03661047) | Massachusetts General Hospital |  No Change | WITHDRAWN | Colon Cancer | PHASE2 | 2019-11-30 | 2021-11-30 | 0 | 2021-11-10 |\n| [NCT04866017](https://clinicaltrials.gov/study/NCT04866017) | BeiGene |  No Change | TERMINATED | Non Small Cell Lung Cancer | PHASE3 | 2021-06-17 | 2023-10-17 | 63 | 2024-10-09 |\n| [NCT05127824](https://clinicaltrials.gov/study/NCT05127824) | Jodi Maranchie |  No Change | RECRUITING | Carcinoma, Renal Cell | PHASE2 | 2023-07-06 | 2026-12 | 42 | 2025-04-30 |\n| [NCT04303169](https://clinicaltrials.gov/study/NCT04303169) | Merck Sharp & Dohme LLC |  No Change | COMPLETED | Melanoma | PHASE1, PHASE2 | 2020-06-26 | 2025-09-24 | 146 | 2025-10-23 |\n| [NCT05329766](https://clinicaltrials.gov/study/NCT05329766) | Arcus Biosciences, Inc. |  No Change | ACTIVE_NOT_RECRUITING | Gastrointestinal Tract Malignancies | PHASE2 | 2022-06-10 | 2027-06 | 332 | 2026-01-27 |\n| [NCT04323202](https://clinicaltrials.gov/study/NCT04323202) | Case Comprehensive Cancer Center |  No Change | COMPLETED | Basal Cell Carcinoma of the Head and Neck | PHASE1 | 2020-08-04 | 2025-06-25 | 13 | 2025-10-23 |\n| [NCT07221253](https://clinicaltrials.gov/study/NCT07221253) | AstraZeneca |  No Change | RECRUITING | Biliary Tract Cancer | PHASE3 | 2025-12-04 | 2029-07-04 | 1100 | 2026-01-07 |\n| [NCT05676931](https://clinicaltrials.gov/study/NCT05676931) | Gilead Sciences |  No Change | ACTIVE_NOT_RECRUITING | Advanced Non-Small Cell Lung Cancer | PHASE2 | 2023-02-21 | 2027-12 | 400 | 2025-09-29 |\n| [NCT06790706](https://clinicaltrials.gov/study/NCT06790706) | Hospices Civils de Lyon |  No Change | RECRUITING | Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor | PHASE2 | 2025-10-01 | 2031-06 | 154 | 2025-10-01 |\n| [NCT04543617](https://clinicaltrials.gov/study/NCT04543617) | Hoffmann-La Roche |  No Change | ACTIVE_NOT_RECRUITING | Esophageal Squamous Cell Carcinoma | PHASE3 | 2020-09-28 | 2027-03-31 | 760 | 2026-01-16 |\n| [NCT04305041](https://clinicaltrials.gov/study/NCT04305041) | Merck Sharp & Dohme LLC |  No Change | COMPLETED | Melanoma | PHASE1, PHASE2 | 2020-06-26 | 2025-08-25 | 100 | 2025-08-28 |\n| [NCT06996782](https://clinicaltrials.gov/study/NCT06996782) | AstraZeneca |  No Change | RECRUITING | Advanced or Metastatic Non-small Cell Lung Cancer | PHASE1, PHASE2 | 2025-11-24 | 2029-02-23 | 152 | 2026-01-13 |\n| [NCT05665595](https://clinicaltrials.gov/study/NCT05665595) | Merck Sharp & Dohme LLC |  No Change | COMPLETED | Melanoma | PHASE3 | 2023-01-19 | 2025-09-26 | 1594 | 2025-10-03 |\n| [NCT06868277](https://clinicaltrials.gov/study/NCT06868277) | AstraZeneca |  No Change | RECRUITING | Carcinoma, Non-Small Cell Lung | PHASE3 | 2025-04-10 | 2030-12-02 | 830 | 2026-01-12 |\n| [NCT06692738](https://clinicaltrials.gov/study/NCT06692738) | AstraZeneca |  No Change | RECRUITING | Non-small Cell Lung Cancer | PHASE3 | 2024-11-18 | 2029-10-08 | 880 | 2026-01-20 |\n| [NCT04774484](https://clinicaltrials.gov/study/NCT04774484) | Francesc Marti |  No Change | WITHDRAWN | End Stage Renal Disease | NA | 2023-01 | 2026-06-30 | 0 | 2023-02-10 |\n| [NCT04256421](https://clinicaltrials.gov/study/NCT04256421) | Hoffmann-La Roche |  No Change | COMPLETED | Small Cell Lung Cancer | PHASE3 | 2020-02-04 | 2025-07-31 | 490 | 2026-01-09 |\n| [NCT06989112](https://clinicaltrials.gov/study/NCT06989112) | AstraZeneca |  No Change | RECRUITING | Endometrial Cancer | PHASE3 | 2025-03-27 | 2031-02-19 | 600 | 2026-01-14 |\n| [NCT05816460](https://clinicaltrials.gov/study/NCT05816460) | University College Dublin |  No Change | UNKNOWN | Insomnia, Cancer | NA | 2023-05-22 | 2024-06-10 | 308 | 2023-05-19 |\n| [NCT06627647](https://clinicaltrials.gov/study/NCT06627647) | AstraZeneca |  No Change | RECRUITING | Non-squamous Non-small Cell Lung Cancer | PHASE3 | 2024-11-27 | 2030-03-25 | 878 | 2025-12-19 |\n| [NCT04305054](https://clinicaltrials.gov/study/NCT04305054) | Merck Sharp & Dohme LLC |  No Change | ACTIVE_NOT_RECRUITING | Melanoma | PHASE1, PHASE2 | 2020-07-01 | 2026-04-20 | 315 | 2025-08-28 |\n| [NCT04294810](https://clinicaltrials.gov/study/NCT04294810) | Hoffmann-La Roche |  No Change | COMPLETED | Non-Small Cell Lung Cancer | PHASE3 | 2020-03-04 | 2025-12-30 | 620 | 2026-01-29 |\n| [NCT03198546](https://clinicaltrials.gov/study/NCT03198546) | Second Affiliated Hospital of Guangzhou Medical University |  No Change | RECRUITING | Hepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer | PHASE1 | 2017-07-01 | 2036-08-01 | 30 | 2024-06-22 |\n| [NCT03198052](https://clinicaltrials.gov/study/NCT03198052) | Second Affiliated Hospital of Guangzhou Medical University |  No Change | RECRUITING | Lung Cancer, Cancer, Immunotherapy, CAR-T Cell | PHASE1 | 2017-07-01 | 2036-08-01 | 30 | 2024-06-22 |\n| [NCT04585815](https://clinicaltrials.gov/study/NCT04585815) | Pfizer |  No Change | TERMINATED | Carcinoma, Non-Small-Cell Lung | PHASE1, PHASE2 | 2020-11-10 | 2024-10-29 | 34 | 2025-12-18 |\n| [NCT02443155](https://clinicaltrials.gov/study/NCT02443155) | Novo Nordisk A/S |  No Change | COMPLETED | Diabetes, Diabetes Mellitus, Type 1 | PHASE2 | 2015-11-10 | 2019-02-27 | 308 | 2021-03-10 |\n\n\n[View Full Change History](history.qmd)\n\n",
    "supporting": [
      "index_files"
    ],
    "filters": [],
    "includes": {}
  }
}